Epidemiology of Asthma in
Selected Pacific countries

Sunia Foliaki

A thesis presented in partial fulfilment of the requirements
for the degree of
Doctor of Philosophy
in Epidemiology
at Massey University, Wellington, New Zealand

May 2007
Abstract

Background

In this thesis, I describe a series of studies of the prevalence, causes, and management of asthma in the Pacific. The core study of the thesis is Phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). The ISAAC study is the largest worldwide epidemiological study on asthma prevalence and was established partly in response to the increases in asthma prevalence in most parts of the world over the last two to three decades. The ISAAC Phase I study found large variations in asthma prevalence globally, but no Pacific countries were involved. Thus, the situation in the Pacific was relatively unknown due to lack of standardised studies on prevalence and time trends. The burden and impact of other non-communicable diseases such as cardiovascular and other metabolic disorder on the other hand have been the target of various studies in the Pacific for the past few decades. The ISAAC Phase III study was therefore conducted in eight Pacific countries to address the above issues, as well as to enhance Pacific participation and contribution to international research on the causes and control of asthma. The collaboration also served the purpose of encouraging and strengthening health research capacity in the Pacific. The ISAAC Phase III study was followed by an asthma self-management intervention trial conducted in Tonga by the ISAAC Tonga study team.

Methods

The work presented in this thesis involved: (i) the conduct of the ISAAC Phase III study in the six Pacific islands of Tokelau, Samoa, Fiji Islands, Tonga, Niue and the Cook Islands, as well as the incorporation into the analysis of data that had already
been collected in French Polynesia and New Caledonia; (ii) analysis of the data from an environmental asthma risk factor questionnaire which was included in the ISAAC survey in three countries (Samoa, Fiji and Tokelau); (iii) the conduct of the Tonga Asthma Self-management Study which was intended to assess whether the introduction of asthma education, including asthma self-management plans, would reduce morbidity from asthma.

Results

A total of 20,876 13-14 year olds, in the eight countries involved, participated in the ISAAC Phase III survey, with an overall response rate of 92%. The survey showed that there was considerable variation in the prevalence of asthma symptoms between the eight countries, ranging from 5.8% for current wheeze in Samoa to 16.2% in Tonga. Tokelau reported the highest prevalence (19.7%) for current wheeze, but the number of participants was relatively small. The prevalences of asthma symptoms among Pacific children in the Pacific were lower than those reported for Pacific, Māori and European children living in New Zealand from a previous study (ISAAC Phase I) conducted ten years earlier using the same methodology. The prevalence of ‘asthma ever’ in Pacific children living in the Pacific was also lower than that found among Pacific, Māori and European children in New Zealand.

The ISAAC Phase III environmental questionnaire data was collected in Samoa, Fiji and Tokelau. The analyses indicated that the major factors associated with current wheeze (across the three countries) were paracetamol use in the previous year (odds ratio (OR) = 1.36, 95% CI 1.15-1.61), the use of open fires for cooking (OR = 1.34, 95% CI 1.13-1.58), lack of physical activity as indicated by television viewing more
than 3 hours per day (OR = 1.24, 95% CI 1.04-1.47), regular meat consumption (OR = 1.30, 95% CI 1.09-1.54) and regular cereal consumption (OR = 1.29, 95% CI 1.07-1.54). However, these risk factors were not particular strong, and did not account for a large proportion of asthma cases (i.e. they had relatively low population attributable risks).

The asthma self-management plan intervention study resulted in significant improvements in asthma morbidity and the management of asthma among individuals and the service provision. The success of the introduction of the self-management plan, in the context of an asthma clinic, was reflected by improvement in measures of asthma morbidity, such as peak expiratory flow rates and nights woken with asthma or coughing. There was also a reduction in the requirement for acute medical treatment, indicated by a decrease in emergency department hospital visits for asthma and hospital admissions. The programme was so successful that the intervention study evolved into a full regular asthma clinic for the main island of Tonga. It is now intended that the asthma self-management programme will be extended throughout the rest of Tonga, through the primary health care system.

Conclusions

The ISAAC Phase III survey has shown that, although there is a significant level of morbidity, asthma prevalence in Pacific countries is lower than those among Pacific people in New Zealand. Together with the large variations in prevalence between the six Pacific countries that participated, this further lends support for the role of environmental risk factors in asthma. The availability of data on eight countries using a standardised methodology also provides useful information on the burden of asthma
in the Pacific that is comparable to other countries regionally and internationally as well as forming a basis for ascertaining trends in the future. The crucial role of asthma self-management plans in asthma management is supported by the findings of the Tonga study, and its implementation is essential in the resource-scarce Pacific health setting. The collaborative nature of ISAAC in the Pacific has further raised awareness of the need for capacity building and creating networks and environments that enhance health research in areas other than asthma. The study has also nurtured an environment and network that encourages and strengthens the establishment of health research as one of the vital tools for achieving better health.
Acknowledgements

The ISAAC study was supported by a Fellowship from the Wellcome Trust (UK) for research into the epidemiology of asthma and other non-communicable diseases in the Pacific and hosted by the Centre for Public Health Research (Massey University). The asthma self-management study (Chapter Seven) was partially funded by the Wellcome Trust, the Health Research Council of New Zealand and Massey University.

To the smiling faces of school children from the Pacific countries, parents and families, this study was always for you and belongs to you. 'Ofa atu.

To Professor Neil Pearce whose academic shoulders many of us have stood on to be within reach of and acquire a better context of the horizon. Without your tireless encouragement and guidance the duration for the completion of this thesis would have involved a prolonged life span mankind would envy. This thesis is one small component of the whole, gained from you as a teacher and a person; to which I am a most grateful recipient. Malo

I also thank my second supervisor, Associate Professor Jeroen Douwes for his support for this work.

To Ms. Soo Cheng, thank you for the willingness and your time dedicated to helping me with the data analysis. It has made life easier.
To the Centre for Public Health Research. It is an honour to work in a Centre peopled with dedicated researchers from New Zealand/Aotearoa as well as a home away from home for international researchers bearing flags of various colours.

To the little people, Tupou ‘Ana Manu, ‘Amanaki, Piula, Moana (Laungā’eiki) and Mesake (Pipi). Stay with me and I will continue to learn, remember and have peace.

To my father Sione Foliaki Moala of Ha’afeva, who sent me to school and church, your departure has only highlighted the urgency of the need to live as you lived.

# Table of Contents

Abstract ............................................................................................................................................. i  
Acknowledgements ............................................................................................................................ v  
List of Figures ..................................................................................................................................... ix  
List of Tables ...................................................................................................................................... x  
Abbreviations ................................................................................................................................... xi  
Chapter 1: Introduction ...................................................................................................................... 1  
1.1 Health Research in the Pacific ........................................................................................................ 1  
1.2 Overview of thesis .......................................................................................................................... 6  
Chapter 2: Asthma Prevalence ........................................................................................................... 8  
2.1 Historical ....................................................................................................................................... 8  
2.2 Clinical Diagnosis of Asthma ....................................................................................................... 11  
2.3 Measuring Asthma Prevalence ..................................................................................................... 16  
2.4 Studies of Asthma Prevalence ..................................................................................................... 25  
2.5 Discussion .................................................................................................................................... 40  
Chapter 3: Asthma Risk Factors ......................................................................................................... 41  
3.1. Introduction .................................................................................................................................. 41  
3.2. “Established” risk factors .......................................................................................................... 42  
3.3. The Allergen Hypothesis ........................................................................................................... 62  
3.4. The “hygiene” hypothesis .......................................................................................................... 72  
3.5. Discussion ................................................................................................................................... 80  
Chapter 4: ISAAC in the Pacific .......................................................................................................... 82  
4.1 Study Rationale and Aims ........................................................................................................... 83  
4.2. Study Design ................................................................................................................................. 97  
Chapter 5: Findings: Asthma Prevalence ......................................................................................... 108  
5.1. Response rates ............................................................................................................................. 108  
5.2. Study participants ....................................................................................................................... 110  
5.3. Prevalence .................................................................................................................................. 110  
5.4. Discussion ................................................................................................................................... 116  
Chapter 6: Findings: Asthma Risk Factors ....................................................................................... 123  
6.1 Prevalence of environmental risk factors ..................................................................................... 123  
6.2 Associations of environmental factors with asthma prevalence ................................................ 127  
6.3 Discussion .................................................................................................................................... 147
## Chapter 7: The Tonga Asthma Self-management Trial

- **7.1 Background** ................................................................. 156
- **7.2 The Tonga Asthma Self-management Trial** ................ 162
- **7.3 Study design and methods** ......................................... 164
- **7.4 Results** ................................................................... 170
- **7.5 Discussion** .............................................................. 174

## Chapter 8: Discussion

- **8.1 Summary of findings** .................................................. 182
- **8.2 Public Health Implications** ......................................... 186
- **8.3 Policy Implications** ..................................................... 193
- **8.4 Issues for Future Research** .......................................... 194
- **8.5 Conclusions** ............................................................ 196

## References ......................................................................... 199

## Appendices ......................................................................... 222
List of figures

Figure 2.1: Phase 1 screening questionnaire for the European Community Respiratory Health Survey (ECRHS) .......................................................... 19

Figure 2.2: ISAAC asthma symptom questionnaire ..................................................... 20

Figure 2.3: ISAAC asthma video questionnaire ............................................................. 21

Figure 7.1: The Self Management Plan (PEFR based) .................................................... 167

Figure 7.2: The Self Management Plan (symptom based) ................................................. 167

Figure 7.3: Monthly Diary Questions ............................................................................. 169
List of tables

Table 2.1: Changes in asthma prevalence in children and young adults .......... 34
Table 3.1: Recent infant cohort studies ................................................................. 43
Table 5.1: Characteristics of participating centres and response rates for 13-14 year olds ................................................................. 109
Table 5.2: Participant characteristics for 13-14 year olds .............................. 111
Table 5.3: Prevalence of asthma symptoms in 6-7 year olds .......................... 112
Table 5.4: Prevalence of asthma symptoms for 13-14 year olds (written questionnaire) ................................................................. 113
Table 5.5: Prevalence of asthma symptoms for 13-14 year olds (video questionnaire) ................................................................. 114
Table 6.1: Prevalence of environmental risk factors by country for 13-14 year olds ................................................................................. 125
Table 6.2: Prevalence odds ratios for various environmental risk factors in Fiji, adjusted for age and gender ................................................................. 130
Table 6.3: Prevalence odds ratios for various environmental risk factors in Samoa, adjusted for age and gender ................................................................. 133
Table 6.4: Prevalence odds ratios for various environmental risk factors in Tokelau, adjusted for age and gender ................................................................. 136
Table 6.5: Environmental risk factors for all countries, adjusted for age, gender and country ................................................................. 141
Table 6.6: Environmental risk factors for all countries: multivariate analysis. .... 144
Table 7.1: Morbidity measures and medication use for enrolled participants at baseline and for “completed” participants at baseline and at 12 months of follow-up ................................................................. 172
Table 7.2: Acceptability of Management Plan at 12 months of follow-up .......... 174
Abbreviations

BHR Bronchial hyperresponsiveness
BMI Body Mass Index
CI Confidence Interval
Can f 1 Dog allergen
Can f 2 Dog allergen
Fel d 1 Cat allergen
Der p 1 Dermatophagoides pteronyssinus allergen
Der f 1 Dermatophagoides farinae allergen
ECRHS European Community Respiratory Health Survey
EQ Environmental Questionnaire
FEV$_1$ Forced Expired Volume in 1 second
FVC Forced Vital Capacity
GINA Global Initiative for Asthma
GNP Gross National Product
HDM House Dust Mite
IgE Immunoglobulin-E
ISAAC International Study of Asthma and Allergies in Childhood
OR Odds Ratio
PEF Peak Expiratory Flow
PEFR Peak Expiratory Flow Rate
POR Prevalence Odds Ratio